Clinical significance of RET/PTC and p53 protein expression in sporadic papillary thyroid carcinoma

Histopathology

Volumn 50, Issue 2, 2007, Pages 225-231

  Zafon, C ^a   Obiols, G ^a   Castellvi J ^a   Tallada, N ^a   Baena, J A ^a   Simo R ^a   Mesa, J ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

p53; Papillary thyroid carcinoma; Prognostic factors; RET PTC

Indexed keywords

MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; PROTEIN P53; THYROXINE;

ADULT; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; ECTOPIC THYROID GLAND; FEMALE; HEALTH STATUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; THYROID CARCINOMA;

ADULT; CARCINOMA; FEMALE; HUMANS; MALE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33846005122     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2006.02555.x     Document Type: Article

References (54)

1. Ain KB. Papillary thyroid carcinoma. Etiology, assessment, and therapy. Endocrinol. Metab. Clin. N. Am. 1995; 24; 711-760.
2. Fusco A, Grieco M, Santoro M et al. A new oncogene in human papillary carcinomas and their lymph-nodal metastases. Nature 1987; 328; 170-172.
3. Lanzi C, Borrello MG, Bongarzone I et al. Identification of the product of two oncogenic rearranged forms of the RET proto-oncogene in papillary thyroid carcinomas. Oncogene 1992; 7; 2189-2194.
4. Bongarzone I, Monzini N, Borrello M et al. Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RIa of cyclic AMP-dependent protein kinase A. Mol. Cell. Biol. 1993; 13; 358-366.
5. Tallini G, Asa SL. RET oncogene activation in papillary thyroid carcinoma. Adv. Anat. Pathol. 2001; 8; 345-354.
6. Santoro M, Sabino N, Ishizaka Y et al. Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours. Br. J. Cancer 1993; 68; 460-464.
7. Suarez H. Genetic alterations in human epithelial thyroid tumours. Clin. Endocrinol. 1998; 48; 631-646.
8. Santoro M, Grieco M, Melillo RM, Fusco A, Vecchio G. Molecular defects in thyroid carcinomas: role of the RET oncogene in thyroid neoplastic transformation. Eur. J. Endocrinol. 1995; 133; 513-522.
9. Sugg S, Ezzat S, Rosen IB, Freeman JL, Asa SL. Distinct multiple RET / PTC rearrangements in multifocal papillary thyroid neoplasia. J. Clin. Endocrinol. Metab. 1998; 83; 4116-4122.
10. Tallini G, Santoro M, Helie M et al. RET / PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin. Cancer Res. 1998; 4; 287-294.
11. TPC) in papillary thyroid carcinomas from Saudi Arabia. Cancer 1994; 73; 176-180.
12. Chiapetta G, Toti P, Cetta F et al. The RET / PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions. J. Clin. Endocrinol. Metab. 2002; 87; 364-369.
13. Basolo F, Giannini R, Monaco C et al. Potent mitogenicity of the RET / PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. Am. J. Pathol. 2002; 160; 247-254.
14. Cheung C, Ezzat S, Ramyar L, Freeman JL, Asa SL. Molecular basis of Hurthle cell papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 2000; 85; 878-882.
15. Jhiang SM, Mazzaferri EL. The ret / PTC oncogene in papillary thyroid carcinoma. J. Lab. Clin. Med. 1994; 123; 331-337.
16. Sugg S, Ezzat S, Zheng L, Freeman JL, Rosen IB, Asa SL. Oncogene profile of papillary thyroid carcinoma. Surgery 1999; 125; 46-52.
17. Viglietto G, Chiapetta G, Martinez-Tello FJ et al. RET / PTC oncogene activation is an early event in thyroid carcinogenesis. Oncogene 1995; 11; 1207-1210.
18. Santoro M, Papotti M, Chiapetta G et al. RET activation and clinicopathological features in poorly differentiated thyroid tumors. J. Clin. Endocrinol. Metab. 2002; 87; 370-379.
19. Soares P, Fonseca E, Wyndord-Thomas D, Sobrinho-Simoes M. Sporadic ret-rearranged papillary carcinoma of the thyroid: a subset of slow growing, less agressive thyroid neoplasms. J. Pathol. 1998; 185; 71-78.
20. Levine A, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351; 453-456.
21. Farid NR. p53 mutations in thyroid carcinoma: tidings from an old foe. J. Endocrinol. Invest. 2001; 24; 536-545.
22. Yeo CJ. Tumor suppressor genes: a short review. Surgery 1999; 125; 363-366.
23. Dobashi Y, Sakamoto A, Sugimura H et al. Overexpression of p53 as a possible prognostic factor in human thyroid carcinoma. Am. J. Surg. Pathol. 1993; 17; 375-381.
24. Fagin JA, Matsuo K, Karmakar A, Lin Chen D, Tang S, Koeffler HP. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J. Clin. Invest. 1993; 91; 179-184.
25. Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G, Pierotti MA. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J. Clin. Invest. 1993; 91; 1753-1760.
26. Holm R, Nesland JM. Retinoblastoma and p53 tumour suppressor gene protein expression in carcinomas of the thyroid gland. J. Pathol. 1994; 172; 267-272.
27. Goto A, Sakamoto A, Machinami R. An immunohistochemical analysis of cyclin D1, p53 and p21waf1 / cip1 proteins in tumors originating from the follicular epithelium of the thyroid gland. Pathol. Res. Pract. 2001; 197; 217-222.
28. La Perle KM, Jhiang SM, Capen CC. Loss of p53 promotes anaplasia and local invasion in ret / PTC1-induced thyroid carcinomas. Am. J. Pathol. 2000; 157; 671-677.
29. Powell DJ Jr, Russell JP, Li G et al. Altered gene expression in immunogenic poorly differentiated thyroid carcinomas from RET / PTC3p53- / - mice. Oncogene 2001; 20; 3235-3246.
30. Zafon C, Obiols G, Castellví J et al. Nm23-H1 immunoreactivity as a prognostic factor in differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 2001; 86; 3975-3980.
31. DeGroot LJ, Kaplan E, McCormick M, Strauss F. Natural history, treatment and course of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 1990; 71; 414-421.
32. Ito T, Seyama T, Iwamoto K et al. In vitro irradiation is able to cause RET oncogene rearrangement. Cancer Res. 1993; 53; 2940-2943.
33. Nikifirov YE, Rowland JM, Bove KE, Monforte-Muñoz H, Fagin J. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res. 1997; 57; 1690-1694.
34. Bongarzone I, Fugazzola L, Vignerui P et al. Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid cacinoma. J. Clin. Endocrinol. Metab. 1996; 81; 2006-2009.
35. Fenton CL, Lukes Y, Nicholson D, Dinauer CA, Francis GL, Tuttle M. The ret / PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults. J. Clin. Endocrinol. Metab. 2000; 85; 1170-1175.
36. Fabien N, Paulin C, Santoro M et al. Detection of RET oncogene activation in human papillary thyroid carcinomas by in situ hybridisation. Br. J. Cancer 1992; 66; 1094-1098.
37. Musholt TJ, Musholt PB, Khaladadj N, Schulz D, Scheumann GFW, Klempnauer J. Prognostic significance of RET and NTRK1 rearrangements in sporadic papillary thyroid carcinoma. Surgery 2000; 128; 984-993.
38. Cheung CC, Ezzat S, Feeman JL, Rosen IB, Asa SL. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod. Pathol. 2001; 14; 338-342.
39. Basolo F, Molinaro E, Agate L et al. RET protein expression has no prognostic impact on the long-term outcome of papillary thyroid carcinoma. Eur. J. Endocrinol. 2001; 145; 599-604.
40. Martínez I, Mantilla A, Medano ME et al. High prevalence of RET tyrosine kinase activation in Mexican patients with papillary thyroid carcinomas. Endocr. Pathol. 2001; 12; 113-123.
41. Miki H, Kitaichi M, Masuda E, Komaki K, Yamamoto Y, Monden Y. ret / PTC expression may be associated with local invasion of thyroid papillary carcinoma. J. Surg. Oncol. 1999; 71; 76-81.
42. Mai KT, Vaccani JP, Thomas J, Odell PF. Immunostaining for ret oncogene proteins in papillary thyroid carcinoma: a correlation of ret immunoreactivity and potential of lymph node metastasies. Thyroid 2001; 11; 859-863.
43. Hosal SA, Apel RL, Freeman JL et al. Immunohistochemical localization of p53 in human thyroid neoplasms: correlation with clinical behaviour. Endocr. Pathol. 1997; 8; 21-28.
44. Godballe C, Asschenfeldt P, Jorgensen KE et al. Prognostic factors in papillary and follicular thyroid carcinomas: p53 expression is a significant indicator of prognosis. Laryngoscope 1998; 108; 243-249.
45. Goldenberg JD, Portugal LG, Wenig BL, Ferrer K, Wu JC, Sabnani J. Well-differentiated thyroid carcinomas: p53 mutation status and microvessel density. Head Neck 1998; 20; 152-158.
46. Zedenius J, Larsson C, Wallin G et al. Alterations of p53 and expression of WAF1 / p21 in human thyroid tumors. Thyroid 1996; 6; 1-9.
47. Matias-Guiu X, Cuatrecasas M, Musulen E, Prat J. P53 expression in anaplastic carcinomas arising from papillary thyroid carcinomas. J. Clin. Pathol. 1994; 47; 337-339.
48. Liu MC, Gelmann EP. p53 gene mutations: case study of a clinical marker for solid tumors. Semin. Oncol. 2002; 29; 246-257.
49. Park YK, Park HR, Chi SG, Ushigome S, Unni KK. Overexpression of p53 and absent genetic mutation in clear cell chondrosarcoma. Int. J. Oncol. 2001; 19; 353-357.
50. Simon D, Goretzki PE, Gorolev V et al. Significance of p53 in human tumors. World J. Surg. 1994; 18; 535-541.
51. Koga T, Hashimoto S, Sugio K et al. Heterogeneous distribution of p53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than with p53 gene mutation. Int. J. Cancer 2001; 20; 232-239.
52. sa, ras, p53 mutations and ret / PTC rearrangement in differentiated thyroid carcinoma in a Korean population. Clin. Endocrinol. 1998; 49; 317-323.
53. Ito T, Seyama T, Mizuno T et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res. 1992; 52; 1369-1371.
54. Horie S, Maeta H, Endo K, Ueta T, Takashima K, Terada T. Overexpression of p53 protein and MDM2 in papillary carcinomas of the thyroid: correlations with clinicopathological features. Pathol. Int. 2001; 51; 11-15.